APUSNYSEPharmaceutical PreparationsFiscal year ends December 31

Apimeds Pharmaceuticals US, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$3.50−0.54 (-13.37%)

Close on Oct 19, 2026

Market cap: $6.00M
P/E (TTM): –
Dividend yield: –

Apimeds Pharmaceuticals US, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research & Development	1.63	–	0.10
General & Administrative	10	1.28	0.65
Operating Expenses	12	1.28	–
Operating Income	-12	-1.28	-0.75
Interest Expense	0.28	0.12	0.04
Interest & Investment Income	0.11	0.00	0.01
Other Non-Operating Income	5.91	-0.11	-0.03
Net Income	-6.00	-1.39	-0.78
EPS (Basic)(per share)	-5.50	-1.80	-1.70
EPS (Diluted)(per share)	-5.50	-1.80	-1.70
Shares Outstanding (Basic, Weighted)(shares)	1.09	0.79	0.46
Shares Outstanding (Diluted, Weighted)(shares)	1.09	0.79	0.46

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -7.9%

Financial strength

Current ratio: 0.51
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.06
Dividend yield: –